GLADIO ACECLOFENAC CREAM

  • Abiogen Pharma S.p.A.
  • 031220054

Local treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments such as: tendinitis, tenosynovitis, sprains, bruises, periarthritis, dislocations, lumbago, stiff neck, bursitis, strains and after-effects of trauma.

info_outline View product sheet
Final Price €12.00

Volume discounts

Quantity Unit discount You Save
2 10% €2.40
5 15% €9.00
10 25% €30.00
Quantity
check_circle Available
Shipped within 24 h
  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Other products Others products at unbeatable price

Abiogen Pharma S.p.A.

Discover all products

GLADIO ACECLOFENAC CREAM

Therapeutic indications

Local treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments such as: tendinitis, tenosynovitis, sprains, bruises, periarthritis, dislocations, lumbago, stiff neck, bursitis, strains and after-effects of trauma.

Dosage and method of use

Apply 1.5 to 2 grams of GLADIO 1.5 g / 100 g cream, equal to 4-5 cm, 3 times a day on the affected part or according to a different medical prescription.

Contraindications

Hypersensitivity to the active substance (aceclofenac) or to non-steroidal anti-inflammatory drugs, including acetylsalicylic acid, or to any of the excipients listed in section 6.1. Patients in whom acetylsalicylic acid or NSAIDs aggravate asthma attacks, acute rhinitis or urticaria or who are hypersensitive to these drugs. Patients with a history of hypersensitivity. Although cross-hypersensitivity has not been demonstrated with diclofenac, it is not recommended in patients hypersensitive to diclofenac. The product is also contraindicated in pediatric age, in pregnancy and during lactation (see "Fertility, pregnancy and lactation").

Side effects

The most commonly reported adverse reactions are mild or moderate irritation accompanied by redness and mild itching which disappear upon discontinuation of treatment. Exceptionally, severe skin and soft tissue infectious complications have been reported to occur in conjunction with NSAID treatment during chickenpox. Occasionally (≥1 / 1000 to 1/100) photosensitivity reactions have been reported when treated skin areas have been exposed to strong sunlight without adequate protection. In the following table, the adverse reactions reported during clinical studies and in post-registration experience with aceclofenac are presented and grouped by systemic and organ class (SOC) and by frequency. Very common (≥ 1/10); common (≥1 / 100,

MedDRa SOC Common (≥1 / 100, Uncommon (≥ 1/1000, Rare (≥1 / 10,000, Very rare (
Skin and subcutaneous tissue disorders   Photosensitivity, erythema, itching.   Bullous reactions (including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis)

Special warnings

For external use only. GLADIO 1.5 g / 100 g cream should not be applied to open sores or wounds. Avoid contact with eyes or mucous membranes or any other application site with ongoing skin lesions. If the use of aceclofenac cream causes symptoms of local irritation, administration should be discontinued and appropriate therapeutic treatment initiated. Avoid inappropriate exposure of the treated area to sunlight without adequate protection to prevent photosensitivity reactions.Hypersensitivity and skin reactions: Prolonged use of products for dermatological use can give rise to sensitization phenomena. As with other NSAIDs, allergic reactions, including anaphylactic / anaphylactoid reactions, may occur even in the absence of previous drug exposure. Very rarely, severe skin reactions, some fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported with concomitant use of NSAIDs (see section 4.8). Patients appear to be at a higher risk for these reactions at the start of therapy as, in most cases, the reaction occurs in the first month of treatment. Aceclofenac should be discontinued as soon as skin rash, mucosal lesions or any other signs of hypersensitivity occur. The safety and efficacy of aceclofenac in children up to 14 years of age have not yet been established. No data are available in this regard. Exceptionally, chickenpox can cause severe infectious skin and soft tissue complications. To date, the role of NSAIDs in the aggravation of these infections cannot be ruled out. It is therefore advisable to avoid the use of aceclofenac in case of chickenpox.

Pregnancy and breastfeeding

Although no teratogenic effects were observed in experimental studies, the safety of aceclofenac in pregnant and lactating women has not been established, therefore administration is not recommended in these circumstances. It is not currently known whether GLADIO is excreted in breast milk, therefore it is not recommended to use the product during the lactation period. The use of GLADIO, as with any prostaglandin synthesis and cyclooxygenase inhibitor drug, is not recommended in women intending to become pregnant. Administration of GLADIO should be discontinued in women who have fertility problems or who are undergoing fertility investigations.

Expiry and retention

Store at a temperature not exceeding 30 ° C.

Interactions with other drugs

Although information on the interactions of aceclofenac cream is not yet available, caution is recommended when used with lithium, digoxin, oral anticoagulants, diuretics and pain relievers.

Overdose

There are no known cases of overdose. In case of improper use or accidental ingestion, intervene with general therapeutic measures of the type normally adopted in case of poisoning with non-steroidal anti-inflammatory drugs.

Active principles

100 g of cream contain:Active principleaceclofenac 1.5 g. Excipients with known effectspropyl parahydroxybenzoate, methyl parahydroxybenzoateFor the full list of excipients, see section 6.1.

Excipients

Emulsifying wax, liquid paraffin,propyl parahydroxybenzoate, methyl parahydroxybenzoate, purified water.

031220054

Data sheet

Packaging
1 -5 g / 100 g cream 50 g tube
1,5 g/100 g crema tubo 50 g
Product Type
HUMAN DRUG
ATC code
M02AA25
ATC description
Aceclofenac
Therapeutic Group
NSAID analgesics
Active principle
aceclofenac (FU)
Class
C.
Pharmaceutical form
cream
Type of Administration
topical
Container
tube
Quantity
1 tube
Capacity
50 grams
Quantity of the Active Ingredient
1 -5G
1.5G
Recipe required
SOP - non-prescription medicine
chat Comments (0)
Fast Order